Association of Obesity and Cardiovascular Outcomes in Atrial Fibrillation
Launched by AJOU UNIVERSITY SCHOOL OF MEDICINE · Dec 2, 2022
Trial Information
Current as of July 31, 2025
Unknown status
Keywords
ClinConnect Summary
This clinical trial is looking at how obesity, measured by body mass index (BMI) and waist circumference, affects health outcomes in patients with atrial fibrillation (AF) who are taking blood-thinning medications called oral anticoagulants (OAC). The study focuses on patients across Asia who were diagnosed with AF between January 2015 and December 2020. Researchers want to understand if being overweight or obese influences the effectiveness of the treatment and overall health for these patients.
To be eligible for this trial, participants must be new users of OAC and diagnosed with AF within the specified timeframe. However, individuals under 20 years old, those with valvular AF, or those who may need OAC for other reasons, like recent surgery or cancer, cannot take part. If you or a loved one meet these criteria, you may be able to contribute to important findings that could help improve care for patients with AF in the future.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Oral anticoagulant (OAC) new users diagnosed with atrial fibrillation (AF) between January 2015 and December 2020
- Exclusion Criteria:
- • Patients aged \<20 years
- • Valvular AF patients
- • Possible alternative indications for OAC (pulmonary embolism, deep vein thrombosis, or recent joint replacement surgery)
- • Cancer patients
About Ajou University School Of Medicine
Ajou University School of Medicine is a leading academic institution dedicated to advancing medical research and education. Located in South Korea, the School of Medicine is renowned for its commitment to innovative clinical trials that aim to improve patient outcomes and enhance healthcare practices. With a focus on multidisciplinary collaboration, Ajou University fosters a research environment that integrates cutting-edge technologies and scientific inquiry. The institution is dedicated to ethical standards and regulatory compliance, ensuring the safety and welfare of participants in all clinical studies. Through its robust training programs and partnerships, Ajou University School of Medicine aims to contribute significantly to the global medical community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Suwon, Gyeong Gido, Korea, Republic Of
Patients applied
Trial Officials
Kwang-No LEE
Principal Investigator
Ajou University School of Medicine
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials